Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies (2019)
Type of ContentJournal Article
- Science: Journal Articles 
Background: Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into the causes of Parkinson's disease. Methods: We did a meta-analysis of 17 datasets from Parkinson's disease GWAS available from European ancestry samples to nominate novel loci for disease risk. These datasets incorporated all available data. We then used these data to estimate heritable risk and develop predictive models of this heritability. We also used large gene expression and methylation resources to examine possible functional consequences as well as tissue, cell type, and biological pathway enrichments for the identified risk factors. Additionally, we examined shared genetic risk between Parkinson's disease and other phenotypes of interest via genetic correlations followed by Mendelian randomisation. Findings: Between Oct 1, 2017, and Aug 9, 2018, we analysed 7·8 million single nucleotide polymorphisms in 37 688 cases, 18 618 UK Biobank proxy-cases (ie, individuals who do not have Parkinson's disease but have a first degree relative that does), and 1·4 million controls. We identified 90 independent genome-wide significant risk signals across 78 genomic regions, including 38 novel independent risk signals in 37 loci. These 90 variants explained 16–36% of the heritable risk of Parkinson's disease depending on prevalence. Integrating methylation and expression data within a Mendelian randomisation framework identified putatively associated genes at 70 risk signals underlying GWAS loci for follow-up functional studies. Tissue-specific expression enrichment analyses suggested Parkinson's disease loci were heavily brain-enriched, with specific neuronal cell types being implicated from single cell data. We found significant genetic correlations with brain volumes (false discovery rate-adjusted p=0·0035 for intracranial volume, p=0·024 for putamen volume), smoking status (p=0·024), and educational attainment (p=0·038). Mendelian randomisation between cognitive performance and Parkinson's disease risk showed a robust association (p=8·00 × 10−7). Interpretation: These data provide the most comprehensive survey of genetic risk within Parkinson's disease to date, to the best of our knowledge, by revealing many additional Parkinson's disease risk loci, providing a biological context for these risk factors, and showing that a considerable genetic component of this disease remains unidentified. These associations derived from European ancestry datasets will need to be followed-up with more diverse data. Funding: The National Institute on Aging at the National Institutes of Health (USA), The Michael J Fox Foundation, and The Parkinson's Foundation (see appendix for full list of funding sources).
CitationNalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol JC, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, Adarmes-Gómez AD, Aguilar M, Aitkulova A, Akhmetzhanov V, Alcalay RN, Alvarez I, Alvarez V, Barrero FJ, Bergareche Yarza JA, Bernal-Bernal I, Billingsley K, Blazquez M, Bonilla-Toribio M, Boungiorno MT, Brockmann K, Bubb V, Buiza-Rueda D, Cámara A, Carrillo F, Carrión-Claro M, Cerdan D, Chelban V, Clarimón J, Clarke C, Compta Y, Cookson MR, Craig DW, Danjou F, Diez-Fairen M, Dols-Icardo O, Duarte J, Duran R, Escamilla-Sevilla F, Escott-Price V, Ezquerra M, Feliz C, Fernández M, Fernández-Santiago R, Finkbeiner S, Foltynie T, Garcia C, García-Ruiz P, Gomez Heredia MJ, Gómez-Garre P, González MM, Gonzalez-Aramburu I, Guelfi S, Guerreiro R (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet Neurology. 18(12). 1091-1102.
This citation is automatically generated and may be unreliable. Use as a guide only.
Keywords23andMe Research Team; System Genomics of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium; Humans; Parkinson Disease; Genetic Predisposition to Disease; Risk Factors; Databases, Genetic; Genome-Wide Association Study; Genetic Loci
ANZSRC Fields of Research32 - Biomedical and clinical sciences::3209 - Neurosciences::320905 - Neurology and neuromuscular diseases
32 - Biomedical and clinical sciences::3202 - Clinical sciences::320213 - Medical genetics (excl. cancer genetics)
31 - Biological sciences::3105 - Genetics::310511 - Neurogenetics
31 - Biological sciences::3105 - Genetics::310509 - Genomics
RightsAll rights reserved unless otherwise stated
Showing items related by title, author, creator and subject.
Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability Botía J; Nalls MA; Noyce AJ; Nicolas A; Cookson MR; Bandres-Ciga S; Gibbs JR; Hernandez DG; Singleton AB; Reed X; Leonard H; Blauwendraat C; Faghri F; Bras J; Guerreiro R; Tucci A; Kia DA; Houlden H; Plun-Favreau H; Mok KY; Wood NW; Lovering R; R’Bibo L; Rizig M; Chelban V; Trabzuni D; Tan M; Morris HR; Middlehurst B; Quinn J; Billingsley K; Holmans P; Kinghorn KJ; Lewis P; Escott-Price V; Williams N; Foltynie T; Brice A; Danjou F; Lesage S; Corvol JC; Martinez M; Giri A; Schulte C; Brockmann K; Simón-Sánchez J; Heutink P; Gasser T; Rizzu P; Sharma M; Shulman JM; Robak L; Lubbe S; Mencacci NE; Finkbeiner S; Lungu C; Scholz SW; Gan-Or Z; Rouleau GA; Krohan L; van Hilten JJ; Marinus J; Adarmes-Gómez AD; Bernal-Bernal I; Bonilla-Toribio M; Buiza-Rueda D; Carrillo F; Carrión-Claro M; Mir P; Gómez-Garre P; Jesús S; Labrador-Espinosa MA; Macias D; Vargas-González L; Méndez-del-Barrio C; Periñán-Tocino T; Tejera-Parrado C; Diez-Fairen M; Aguilar M; Alvarez I; Boungiorno MT; Carcel M; Pastor P; Tartari JP; Alvarez V; González MM; Blazquez M; Garcia C; Suarez-Sanmartin E; Barrero FJ; Rezola EM; Yarza JAB; Pagola AG; de Munain Arregui AL; Ruiz-Martínez J; Cerdan D; Duarte J; Clarimón J; Dols-Icardo O; Reynolds, Regina (Springer Science and Business Media LLC, 2019)Parkinson’s disease (PD), with its characteristic loss of nigrostriatal dopaminergic neurons and deposition of α-synuclein in neurons, is often considered a neuronal disorder. However, in recent years substantial evidence ...
Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders Nabais MF; Laws SM; Lin T; Vallerga CL; Armstrong NJ; Blair IP; Kwok JB; Mather KA; Mellick GD; Sachdev PS; Wallace L; Henders AK; Zwamborn RAJ; Hop PJ; Lunnon K; Pishva E; Roubroeks JAY; Soininen H; Tsolaki M; Mecocci P; Lovestone S; Kłoszewska I; Vellas B; Furlong S; Garton FC; Henderson RD; Mathers S; McCombe PA; Needham M; Ngo ST; Nicholson G; Pamphlett R; Rowe DB; Steyn FJ; Williams KL; Anderson TJ; Bentley SR; Fowder J; Gratten J; Halliday G; Hickie IB; Kennedy M; Lewis SJG; Montgomery GW; Pearson J; Pitcher TL; Silburn P; Zhang F; Visscher PM; Yang J; Stevenson AJ; Hillary RF; Marioni RE; Harris SE; Deary IJ; Jones AR; Shatunov A; Iacoangeli A; van Rheenen W; van den Berg LH; Shaw PJ; Shaw CE; Morrison KE; Al-Chalabi A; Veldink JH; Hannon E; Mill J; Wray NR; McRae AF; Dalrymple-Alford, John (Springer Science and Business Media LLC, 2021)Background: People with neurodegenerative disorders show diverse clinical syndromes, genetic heterogeneity, and distinct brain pathological changes, but studies report overlap between these features. DNA methylation (DNAm) ...
Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson’s disease Vallerga CL; Zhang F; Fowdar J; McRae AF; Qi T; Nabais MF; Zhang Q; Kassam I; Henders AK; Wallace L; Montgomery G; Chuang YH; Horvath S; Ritz B; Halliday G; Hickie I; Kwok JB; Pearson J; Pitcher T; Kennedy M; Bentley SR; Silburn PA; Yang J; Wray NR; Lewis SJG; Anderson T; Mellick GD; Visscher PM; Gratten J; Dalrymple-Alford, John (Springer Science and Business Media LLC, 2020)An improved understanding of etiological mechanisms in Parkinson’s disease (PD) is urgently needed because the number of affected individuals is projected to increase rapidly as populations age. We present results from a ...